CREEK & RIVER (4763) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
20 Jul, 2026Executive summary
Q1 FY02/26 achieved record-high quarterly sales of ¥13,839 million, with operating profit up 12.7% and net profit attributable to owners at ¥913 million, both showing double-digit year-over-year growth.
Gaming and medical segments, previously underperforming, are showing recovery.
Two new subsidiaries, T & W Office Co., Ltd. and Takahashi Shoten Group, were added to the consolidation scope, increasing total assets by ¥20 billion.
Comprehensive income for the quarter was ¥878 million, slightly down 0.7% year-over-year.
Financial highlights
Sales: ¥13,839 million, up 8% year-over-year; operating profit: ¥1,421 million, up 13% year-over-year; ordinary profit: ¥1,406 million, up 10% year-over-year; net profit attributable to owners: ¥913 million, up 6% year-over-year.
Gross profit margin: 38.6% (down 0.7pt year-over-year); gross profit increased to ¥5,340 million.
Basic earnings per share for the quarter were ¥43.20, up from ¥39.67 a year earlier.
Total assets surged to ¥47,870 million as of May 31, 2025, from ¥27,078 million at the previous fiscal year-end.
Net assets were ¥16,067 million, with an equity-to-asset ratio of 33.1%.
Outlook and guidance
Full-year forecasts are progressing as planned, with FY Feb 2026 sales projected at ¥60 billion (+10% YoY) and operating profit at ¥5 billion (+38% YoY).
Profit attributable to owners of parent expected at ¥3,200 million, up 42.1%.
Takahashi Shoten Group expected to contribute ¥4.9 billion in sales and ¥500 million in operating profit for the year.
Dividend per share forecasted at ¥45, payout ratio 30%.
No revisions to previously announced earnings or dividend forecasts.
Latest events from CREEK & RIVER
- Sales up 1% but operating profit down 20.2% YoY; strong full-year recovery forecast.4763
Q1 202420 Jul 2026 - Sales up 2.3% but operating profit down 15.6%; AI/DX and overseas growth prioritized.4763
Q2 202420 Jul 2026 - Sales up 1% YoY, profits down double digits, dividend cut, treasury buyback and new initiatives.4763
Q3 202520 Jul 2026 - Record sales and lower profits in FY2025; strong growth and higher dividends forecast for FY2026.4763
Q4 202520 Jul 2026 - Net sales rose 8.7% and profit attributable to owners of parent surged 50.7%.4763
Q2 202620 Jul 2026 - Record sales and profit growth fueled by new segments, M&A, and strong business performance.4763
Q3 202620 Jul 2026 - Record sales and double-digit profit growth, with sales growth forecast to continue.4763
Q4 202620 Jul 2026 - Record Q1 sales and profits, driven by creative, medical, and incubation growth.4763
Q1 202720 Jul 2026